4SCAR-CD44v6 T Cell Therapy / SZGIMI - LARVOL DELTA

4SCAR-CD44v6 T Cell Therapy Targeting Cancer (clinicaltrials.gov) - P1/2 | N=100 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2030 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2029 ➔ Jul 2026

Trial completion date • Trial primary completion date • Trial termination • Oncology

4SCAR-CD44v6 T Cell Therapy Targeting Cancer (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2030 | Trial primary completion date: May 2023 ➔ Dec 2029

Trial completion date • Trial primary completion date • Oncology

4SCAR-CD44v6 T Cell Therapy Targeting Cancer (clinicaltrials.gov) - P1/2; N=100; Recruiting; Sponsor: Shenzhen Geno-Immune Medical Institute

Clinical • New P1/2 trial • Oncology